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ABSTRACT
Activated B-cells increase T-cell behaviour during autoimmune disease and other 
infections by means of cytokine production and antigen-presentation. Functional 
studies in experimental autoimmune encephalomyelitis (EAE) indicate that B-cell 
deficiencies, and a lack of IL10 and IL35 leads to a poor prognosis. We hypothesised 
that B-cells play a role during tuberculosis. We evaluated B-cell mRNA expression 
using real-time PCR from healthy community controls, individuals with other lung 
diseases and newly diagnosed untreated pulmonary TB patients at three different 
time points (diagnosis, month 2 and 6 of treatment). 
We show that FASLG, IL5RA, CD38 and IL4 expression was lower in B-cells from 
TB cases compared to healthy controls. The changes in expression levels of CD38 may 
be due to a reduced activation of B-cells from TB cases at diagnosis. By month 2 of 
treatment, there was a significant increase in the expression of APRIL and IL5RA in 
TB cases. Furthermore, after 6 months of treatment, APRIL, FASLG, IL5RA and CD19 
were upregulated in B-cells from TB cases. The increase in the expression of APRIL 
and CD19 suggests that there may be restored activation of B-cells following anti-TB 
treatment. The upregulation of FASLG and IL5RA indicates that B-cells expressing 
regulatory genes may play an important role in the protective immunity against M.tb 
infection. Our results show that increased activation of B-cells is present following 
successful TB treatment, and that the expression of FASLG and IL5RA could potentially 
be utilised as a signature to monitor treatment response.
INTRODUCTION
T-cell driven cell-mediated immunity, has been the 
focus of studies investigating host immunity against M.tb 
infection [1]-[3] and TB disease. However, an increasing 
number of studies are indicating that the role of B-cells 
in the protective immunity against M.tb infection has 
been underestimated. B-cells are the key players during 
humoral immunity and produce antibodies in response to 
invading pathogens. Studies found that humoral immunity 
may enhance protection against M.tb infection [4]-[6]. 
Furthermore, B-cells have additional functions that may 
be essential for host protection during infection and 
disease. Activated B-cells change T-cell behaviour during 
autoimmune disease and other pathogenic infections by 
means of cytokine production and antigen-presentation. 
Effector B-cells can either produce Interferon (IFN)-γ and 
Interleukin (IL)-12 (Be-1 cells) or IL-2, IL-13 and IL-4 
(Be-2 cells) depending on whether the cells are primed 
by Th1 or Th2 cells, respectively [7], [8]. These cytokine-
producing effector B-cells are able to amplify T-cell 
responses in a cytokine-dependent manner [9], [10].
B-cells also display regulatory phenotypes, which 
secrete IL-10, IL-35, and express FAS ligand (FasL). 
Functional studies in EAE indicate that B-cell deficiencies, 
and a lack of IL10 and IL35 lead to a poor prognosis[11]. 
B-cells limited EAE pathogenesis by means of IL-35 
secretion, which decreased the accumulation of pathogenic 
cells in the target organ. FasL-expressing B-cells have a 
similar effect during autoimmune disease. These B-cells 
induce apoptosis of CD4+ T-cells, have the potential to 
reduce the inflammatory responses during autoimmune 
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disease and are induced by IL-5 [12]. High levels of FasL 
expression was observed in B-cells activated via the Toll-
Like Receptor (TLR) 9 agonist CpG [13]. We hypothesised 
that B-cells play a similar role during tuberculosis disease. 
Transcriptional approaches are useful for the discovery 
of biomarkers for the diagnosis and measurement of 
treatment response [14]-[17]. We evaluated patterns in the 
expression of B-cell genes to better our understanding of 
B-cell behaviour during M.tb infection and tuberculosis 
(TB). Real-time PCR was utilised to assess the expression 
of gene transcripts of cytokines, together with genes 
involved in B-cell activation and effector functions.
RESULTS
Comparison of gene expression between TB, OLD 
and Control groups
In order to evaluate the differences in the expression 
of the 12 specific genes in purified B-cells between healthy 
controls (Ctrl), TB cases and individuals with other lung 
diseases (OLD), the delta Ct method was utilised. All 
analyses were carried out by means of the online software 
provided by SABiosciences.
The expression of APRIL, BAFF, CD19, IL4, 
FCGR1A, IL35, IL5RA, TNF and TLR9 was similar 
between Ctrl and OLD groups (p > 0.05) (Table 2). In 
contrast, FASLG and CD38 expression was significantly 
decreased in OLD compared to Ctrl (p < 0.01; Table 2). 
There were no differences in the expression of all the 
genes between individuals with other lung diseases and 
TB cases. When comparing the expression of the genes 
between healthy controls and TB cases, we found that 
there was a significant decrease in the expression of IL4, 
FASLG, IL5RA and CD38 (p < 0.05) (Table 2). The relative 
gene expression changes between the CTRL, OLD and 
TB groups are shown in the form of a heat map (Figure 
1), which demonstrates differential expression of genes 
between the control group and the TB group is evident.
Table 1: Clinical and demographic characteristics of study participants
TB CTRL OLD
No. of Female 8 10 5
No. of Male 12 0 5
QuantiFERON status (Dx) NA POSITIVE
5 POSITIVE
5 NEGATIVE
Sputum-culture status (Dx) POSITIVE NEGATIVE NEGATIVE
Table 2: Gene expression differences between TB and Control Groups
GENES







APRIL -2.08 p > 0.05 -3.03 p > 0.05 -1.46 p > 0.05
TLR9 -1.60 p > 0.05 -2.10 p > 0.05 -1.31 p > 0.05
IL5RA -3.54 p > 0.05 -8.26 p < 0.01 -2.33 p > 0.05
IL4 -7.03 p > 0.05 -10.70 p < 0.01 -1.52 p > 0.05
IL35 -2.77 p > 0.05 -3.35 p > 0.05 -1.21 p > 0.05
FASLG -6.26 p < 0.01 -5.70 p < 0.01 1.10 p > 0.05
FCGR1A -1.78 p > 0.05 1.39 p > 0.05 2.47 p > 0.05
BAFF -1.71 p > 0.05 -1.74 p > 0.05 -1.02 p > 0.05
TNF 1.63 p < 0.05 1.12 p > 0.05 -1.45 p > 0.05
CD38 -6.06 p < 0.01 -6.59 p < 0.01 -1.09 p > 0.05
CD19 1.08 p > 0.05 -1.03 p > 0.05 -1.12 p > 0.05
STAT6 -1.57 p > 0.05 -1.66 p > 0.05 -1.06 p > 0.05
The fold change values represent the changes in gene expression between the respective groups, as calculated 
by SABiosciences online software. Positive values indicate an increase in expression, (negative value indicates a 
decrease in expression) between groups. Kruskal-Wallis tests were used for comparisons, and a p-value < 0.05 is 
considered significant and is highlighted in bold. 
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Figure 1: Differences in mRNA expression between TB and Control groups. Comparison of the average gene expression 
between the respective groups. Where Ctrl are healthy controls, OLD are individuals with other lung diseases and TB are individuals is TB 
disease. Heatmap, which was generated using R statistical packages, depicting changes in normalized expression values (dCt). Genes with 
low expression levels are depicted in yellow, whereas genes with high expression levels are depicted in blue. 
Figure 2: Differential mRNA expression over the course of anti-tuberculosis treatment. Heat map depicting changes in 
normalized expression values (dCt). Genes with low expression levels are depicted in yellow, whereas genes with high expression levels are 
depicted in blue. a. Group comparisons showing gene expression for individual participants. b. Comparison of the average gene expression 
between the respective groups.
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Differential gene expression during Anti-TB 
treatment
The expression of specific genes in purified B-cells 
was compared between diagnosis (before treatment 
started), month two (the time point frequently used to 
evaluate sputum culture conversion) and month six (end 
of treatment) following the initiation of anti-TB treatment. 
There were no significant differences in the expression of 
BAFF, CD19, FASLG, IL4, CD38, FCGR1A, IL35, TNF 
and TLR9 between diagnosis and month 2 of treatment 
(p > 0.05) (Table 3). However, APRIL and IL5RA were 
differentially expressed between these two time points 
with fold changes of 1.85 (p < 0.05) and 1.87 (p < 0.05) 
respectively (Table 3).
When comparing the expression of the 12 genes 
between diagnosis and month six of treatment, APRIL, 
CD19, FASL and IL5RA were differentially expressed 
(Table 3 and Figure 3). There was an increase in the 
expression of all the latter genes at month 6. The 
expression of BAFF, STAT6, IL35, TNF, CD38 and TLR9 
was similar at diagnosis and month six of treatment. The 
relative gene expression is depicted in a heat map for 
individual samples (Figure 2a) and clustered as groups 
(Figure 2 b).
DISCUSSION
B-cells displaying regulatory phenotypes secrete 
cytokines such as IL-10 and IL-35, and also express 
FasL. These FasL-expressing B-cells have predominantly 
been studied in autoimmune diseases and infections [18]. 
A study conducted in mice showed that IL-35 secreted 
by B-cells limited EAE pathogenesis by decreasing the 
accumulation of pathogenic cells in the target organ [11]. 
Similarly, B-cell-deficiencies in mice have been linked to 
a decreased control of Salmonella infection [19]. In the 
current study, FASLG, IL5RA and IL4 expression were 
decreased in TB cases at diagnosis compared to healthy 
controls. In contrast, FASLG and IL5RA expression were 
increased after 6 months in TB cases. These results suggest 
that B-cell activity may be restored following successful 
anti-TB treatment and could play a role in the protective 
immunity against M.tb infection.
CD38 is a membrane-bound protein which is 
expressed on the surface of B-cells throughout their 
lifespan [20]. However, the expression of CD38 is highest 
on B1 B-cells [21]. Crosslinking of the CD38 receptor on 
mature B-cells leads to proliferation, isotype switching 
and reduced apoptosis. Additionally, CD38 acts as a 
co-stimulatory signal to B-cells activated by means of 
TLR ligands [22], [23]. Here we show a decline in the 
expression of CD38 in B-cells from TB participants 
compared to healthy controls. This points to a reduction 
in the activation of B-cells during active M.tb infection. 
APRIL, which is a proliferation inducing ligand, is also 
associated with the activation of B-cells. We found APRIL 
at lower levels in TB participants compared to healthy 
controls. However, the expression of this gene was 
Table 3: Gene expression in TB group over 6 months of treatment 
GENES







APRIL 1.85 p < 0.05 2.06 p < 0.01 1.12 p > 0.05
IL5RA 1.87 p < 0.05 1.96 p < 0.05 1.05 p > 0.05
TLR9 1.18 p > 0.05 1.35 p > 0.05 1.15 p > 0.05
IL4 1.79 p > 0.05 1.84 p > 0.05 1.03 p > 0.05
IL35 1.04 p > 0.05 1.21 p > 0.05 1.17 p > 0.05
FASLG 1.33 p > 0.05 1.87 p < 0.01 1.40 p > 0.05
FCGR1A -1.91 p > 0.05 -2.74 p > 0.05 -1.43 p > 0.05
BAFF 1.13 p > 0.05 1.00 p > 0.05 -1.12 p > 0.05
TNF 1.10 p > 0.05 -1.02 p > 0.05 -1.12 p > 0.05
CD38 1.65 p > 0.05 1.48 p > 0.05 1.11 p > 0.05
CD19 1.49 p > 0.05 1.77 p < 0.05 1.18 p > 0.05
STAT6 1.08 p > 0.05 1.21 p > 0.05 1.12 p > 0.05
The fold change values represent the changes in gene expression between the respective groups, as calculated by 
SABiosciences online software. Positive values indicate an increase in expression, whereas a negative value indicates a 
decrease in expression. Kruskal Wallis tests were used for comparisons, and a p-value ≤ 0.05 is considered significant and is 
highlighted in bold. 
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restored after 6 months of treatment, in addition to CD19. 
Together these results suggest that there is an increase in 
B-cell activation throughout treatment in TB cases. This 
restored B-cell activation may lead to more interactions 
between B-cells and helper T-cells due to the upregulation 
of co-stimulatory molecules [23].
Transcriptional analyses are useful for the 
identification of biomarkers for diagnostics, as well as 
monitoring treatment response during tuberculosis and 
other diseases [14]-[17]. In the current study, FASLG 
and IL5RA was downregulated in TB cases at diagnosis 
compared to healthy controls. The expression of the 
latter genes were upregulated in TB cases at 6 months 
of treatment. Collectively, this suggests that FASLG and 
IL5RA have the potential to be utilised as a biosignature to 
monitor success or failure of treatment. Further studies in 
larger cohorts are required to confirm this.
In conclusion, the results of our pilot study suggest 
that B-cells expressing regulatory genes could be 
involved during the immune response to M.tb infection. 
Previous studies of regulatory B-cells focussed mostly 
on autoimmune diseases and helminth infections. 
Supplementary transcriptional and functional studies 
are required to confirm the precise role that B cells play 
during tuberculosis disease and the mechanisms by which 
the activation/immune induction is achieved.
MATERIALS AND METHODS
Participant recruitment and sample collection
This study was carried out according to the 
guidelines of the ICH-GCP. All participants provided 
written informed consent for participation in the study, 
Figure 3: Genes differentially expressed during anti-TB treatment. Normalized expression values of genes as calculated using 
the dCt method (Ct (gene) - Ct (housekeeping gene)). Statistical differences calculated by means of Kruskal Wallis tests, where significant 
differences are indicated by an asterisk (* = p < 0, 05 or ** = p < 0.01). Data represented as median dCt with bars representing range. High 
dCt values indicate low gene expression, and low dCt values indicate high gene expression. a. APRIL, b. CD19, c. FASL and d. IL5RA.
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and the use and storage of the samples for biomarker 
discovery. Ethical approval was obtained from the Health 
Research Ethics Committee (Ethics number N10/01/013) 
of Stellenbosch University and the Departments of Health 
of the Province of the Western Cape and City of Cape 
Town.
The study participants were recruited from the 
Ravensmead/Uitsig community in Cape Town Western 
Cape. Individuals with newly diagnosed, untreated 
pulmonary TB were enrolled into the study prior to 
commencement of anti-TB treatment. The inclusion 
criteria for the ten healthy controls was a positive IGRA. 
For TB cases we included participants with a chest 
radiograph with suggestive signs of TB, clinical symptoms 
of TB including a chronic cough, weight loss and night 
sweats, as well as a positive sputum-culture and -smear. 
The exclusion criteria included prior cases of TB or other 
lung diseases, and a HIV positive status. In addition, ten 
individuals with a lung disease (other than TB) were 
enrolled into the study. Half of the other lung disease 
(OLDs) (Table 1) were IGRA positive. The individuals in 
the OLD and healthy control (Ctrl) groups did not present 
any clinical symptoms of M.tb infection.
Peripheral blood was collected from the study 
participants into sodium heparin tubes, as well as sputum 
samples for smear/culture tests. The individuals with TB 
were subsequently followed up at month two and month 
six of treatment, where blood and sputum samples were 
collected once more to monitor their response to treatment. 
Thirteen TB cases had converted to culture negative at 
month 2 of treatment, and all TB cases were cured at the 
end of treatment which was confirmed by sputum culture 
tests.
Sample preparation, mRNA isolation and quality 
check
On the day of blood collection, peripheral blood 
mononuclear cells (PBMCs) were isolated using the ficoll/
histopaque separation method (GE Health, Piscataway, 
NJ). Total B-cells were isolated using the MACS bead 
separation method through positive selection (B cell 
isolation kit II, Miltenyi, Germany), and stored in 
RNAlater® (Life Technologies, USA). The cells were 
stored in liquid nitrogen until batch analysis.
The cells were thawed on ice and spun down 
before being washed in Phosphate-buffered saline (PBS). 
Subsequently, mRNA was isolated using the RNEasy® 
Mini Kit (Qiagen, Germany) according to manufacturer’s 
instructions. RNA purity and quantification was assessed 
using NanoDrop 2000 spectrophotometer data. More 
specifically, the 260/ 280 ratio and the 260/ 230 ratio 
were measured to assess the purity of the isolated RNA. 
A 260/280 and 260/230 ratio of at least 1.7 and 1.5 
respectively, was considered sufficiently pure for further 
analysis. The RNA samples were stored at -80 ˚C.
cDNA synthesis and RT-qPCR
The isolated RNA was thawed on ice and diluted 
to a concentration of 300ug, and subsequently used to 
synthesise cDNA. The procedure was carried out in 
a thermal cycler (Life Technologies, USA) using the 
First Strand Kit (Qiagen, Germany) according to the 
manufacturer’s instructions. The cDNA was then used 
as template for quantitative PCR on the ABI 7900HT 
platform. The RT2 Profiler Custom Arrays (Qiagen, 
Germany) were utilised and manufacturer’s instructions 
were followed. The arrays contained primers for the 
following genes of interest: IL35 (NM_000882.3), 
IL4(NM_000589.3), Fas-ligand (FASLG) (NM000639.2), 
IL5RA receptor alpha (IL5RA) (NM_000564.4), 
cluster of differentiation 38 (CD38) (NM_001775.2), 
APRIL (NM_00198622.1), BAFF (NM001145645.2), 
TNF-a (NM_000594.3), Fc gamma receptor 1 alpha 
(FCGR1A) (NM_000566.3), Toll-like receptor 9 (TLR9) 
(NM_017442.3), STAT6 (NM_001178078.1), as well as 
two housekeeping genes B2M (NM_004048) and GAPDH 
(NM_002046). FASLG, IL5RA and IL35 is associated with 
regulatory B-cells. Furthermore, APRIL, CD38 and TLR9 
is involved in B-cells activation.
Data analysis
The gene expression data obtained from the ABI 
7900HT was represented as Ct values, which indicated 
the earliest visible cycle of amplification. These Ct 
values were converted to fold change values using the 
Qiagen online software (www.SABiosciences.com/
pcrarraydataanalysis.php). Where applicable, differences 
were calculated using Prism 5 Software and Kruskal-
Wallis tests, where p < 0.05 indicates a statistically 
significant difference. Heatmaps were generated using 
delta Ct (dCt) data and R statistical packages.
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